Factors associated with the efficacy of omalizumab treatment in chronic spontaneous urticaria
Allergologia et Immunopathologia · 2025
DOI: 10.15586/aei.v53i2.1207 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergologia et Immunopathologia, 2025. Verfasst von Fatma Arzu Akkuş und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology and Allergy, Necmettin Erbakan University, Faculty of Medicine, Konya, Turkey; arzusmr@hotmail.com. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Omalizumab is a preferred treatment in antihistamine-refractory chronic spontaneous urticaria (CSU) patients. However, factors that may impact treatment response remain to be explored.
Objective
This study aimed to examine the factors affecting treatment response in CSU patients receiving omalizumab.
Methods
This was a retrospective study that included 123 patients who received omalizumab treatment for CSU between January 2015 and April 2024. After administering omalizumab, we evaluated therapeutic efficacy with the urticaria control test (UCT). According to UCT, patients were classified as complete responders, partial responders, and nonresponders.
Results
The median age of the patients was 42 (31–50) years, and there were 77 (62.9%) female patients. Sixty-four (52%) patients exhibited complete response, and 43 (35%) patients exhibited partial response to omalizumab treatment, whereas 16 (13%) patients were nonresponders. Autoimmune disease (AID) was present in 31 (25.2%) patients. The most common AID was thyroid autoimmunity, seen in 24 (77.4%) patients. AID was significantly higher in omalizumab treatment nonresponders than in partial and complete responders. The presence of an autoimmune thyroid disease was an independent risk factor for failure to respond to omalizumab treatment. Baseline IgE levels were significantly higher in omalizumab treatment responders with a complete response compared to those with a partial response and nonresponders.
Conclusion
Response to omalizumab treatment was influenced by the presence of an AID and baseline serum total IgE level. A concurrent autoimmune thyroid disease was found to be an independent risk factor affecting failed treatment response. Factors that can predict response to omalizumab treatment can help guide patients to more effective treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology and Allergy, Necmettin Erbakan University, Faculty of Medicine, Konya, Turkey; arzusmr@hotmail.com.
- Department of Clinical Immunology and Allergy, Necmettin Erbakan University, Faculty of Medicine, Konya, Turkey.
- Medical Faculty, Training and Research Hospital, Recep Tayyip Erdoğan University, Rize, Türkiye.
- University of Health Sciences Gülhane Training and Research Hospital, Clinic of Immunology and Allergy Diseases, Ankara, Türkiye.
- Batman Training and Research Hospital, Batman, Türkiye.
Zitieren
APA
Akkuş, F. A., Çölkesen, F., Önalan, T., Evcen, R., Aykan, F. S., Kılınç, M., Gerek, M. E., & Arslan, Ş. (2025). Factors associated with the efficacy of omalizumab treatment in chronic spontaneous urticaria. Allergologia et Immunopathologia. https://doi.org/10.15586/aei.v53i2.1207
Vancouver
Akkuş FA, Çölkesen F, Önalan T, Evcen R, Aykan FS, Kılınç M, et al. Factors associated with the efficacy of omalizumab treatment in chronic spontaneous urticaria. Allergologia et Immunopathologia. 2025. doi:10.15586/aei.v53i2.1207
BibTeX
@article{Akku2025,
author = {Akkuş, Fatma Arzu and Çölkesen, Fatih and Önalan, Tuğba and Evcen, Recep and Aykan, Filiz Sadi and Kılınç, Mehmet and Gerek, Mehmet Emin and Arslan, Şevket},
title = {Factors associated with the efficacy of omalizumab treatment in chronic spontaneous urticaria},
journal = {Allergologia et Immunopathologia},
year = {2025},
doi = {10.15586/aei.v53i2.1207}
}
EUVIMED